↓ Skip to main content

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

blogs
1 blog
twitter
7 X users

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
Published in
Orphanet Journal of Rare Diseases, July 2020
DOI 10.1186/s13023-020-01399-4
Pubmed ID
Authors

Teresa Coelho, David Adams, Isabel Conceição, Márcia Waddington-Cruz, Hartmut H. Schmidt, Juan Buades, Josep Campistol, John L. Berk, Michael Polydefkis, Jing Jing Wang, Jihong Chen, Marianne T. Sweetser, Jared Gollob, Ole B. Suhr

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 11%
Researcher 6 8%
Other 6 8%
Student > Ph. D. Student 5 7%
Unspecified 4 5%
Other 16 21%
Unknown 30 40%
Readers by discipline Count As %
Medicine and Dentistry 13 17%
Pharmacology, Toxicology and Pharmaceutical Science 10 13%
Biochemistry, Genetics and Molecular Biology 6 8%
Unspecified 4 5%
Agricultural and Biological Sciences 3 4%
Other 7 9%
Unknown 32 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2021.
All research outputs
#2,854,087
of 23,220,133 outputs
Outputs from Orphanet Journal of Rare Diseases
#389
of 2,665 outputs
Outputs of similar age
#75,383
of 396,946 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#11
of 59 outputs
Altmetric has tracked 23,220,133 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,665 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 396,946 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.